Changes in Cancer Incidence and Mortality in Australia over the Period 1996-2015

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2020 Dec 11

PMID 33303018

Citations 5

Authors

Qingwei Luo

Julia Steinberg

Dianne L OConnell

Paul B Grogan

Karen Canfell

Eleonora Feletto

Affiliations

Soon will be listed here.

Abstract

Objective: A previous Australian study compared the observed numbers of cancer cases and deaths in 2007 with the expected numbers based on 1987 rates. This study examines the impact of cancer rate changes over the 20-year period 1996-2015, for people aged under 75 years.

Results: The overall age-standardised cancer incidence rate increased from 350.7 in 1995 to 364.4 per 100,000 in 2015. Over the period 1996-2015, there were 29,226 (2.0%) more cases (males: 5940, 0.7%; females: 23,286, 3.7%) than expected numbers based on 1995 rates. Smaller numbers of cases were observed compared to those expected for cancers of the lung for males and colorectum, and cancers with unknown primary. Larger numbers of cases were observed compared to those expected for cancers of the prostate, thyroid and female breast. The overall age-standardised cancer mortality rate decreased from 125.6 in 1995 to 84.3 per 100,000 in 2015. During 1996 to 2015 there were 106,903 (- 20.6%) fewer cancer deaths (males: - 69,007, - 22.6%; females: - 37,896, - 17.9%) than expected based on the 1995 mortality rates. Smaller numbers of deaths were observed compared to those expected for cancers of the lung, colorectum and female breast, and more cancer deaths were observed for liver cancer.

Citing Articles

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study.

Zhou K, Robert M, Seegers V, Blanc-Lapierre A, Savouroux S, Bigot F PLoS One. 2024; 19(5):e0304556.

PMID: 38820299 PMC: 11142554. DOI: 10.1371/journal.pone.0304556.

Trends and projections of cause-specific premature mortality in Australia to 2044: a statistical modelling study.

Luo Q, Steinberg J, Kahn C, Caruana M, Grogan P, Page A Lancet Reg Health West Pac. 2024; 43:100987.

PMID: 38456088 PMC: 10920049. DOI: 10.1016/j.lanwpc.2023.100987.

Identifying cancer driver genes in individual tumours.

Gillman R, Field M, Schmitz U, Karamatic R, Hebbard L Comput Struct Biotechnol J. 2023; 21:5028-5038.

PMID: 37867967 PMC: 10589724. DOI: 10.1016/j.csbj.2023.10.019.

Projections of smoking-related cancer mortality in Australia to 2044.

Luo Q, Steinberg J, Yu X, Weber M, Caruana M, Yap S J Epidemiol Community Health. 2022; .

PMID: 35750482 PMC: 9380484. DOI: 10.1136/jech-2021-218252.

Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.

Luo Q, OConnell D, Yu X, Kahn C, Caruana M, Pesola F Lancet Public Health. 2022; 7(6):e537-e548.

PMID: 35660215 PMC: 9159737. DOI: 10.1016/S2468-2667(22)00090-1.

References

Luo Q, Steinberg J, OConnell D, Yu X, Caruana M, Wade S . Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?. Lung Cancer. 2019; 130:208-215. DOI: 10.1016/j.lungcan.2019.02.028. View

Degeling K, Baxter N, Emery J, Jenkins M, Franchini F, Gibbs P . An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. Asia Pac J Clin Oncol. 2021; 17(4):359-367. PMC: 8014813. DOI: 10.1111/ajco.13505. View

Adair T, Hoy D, Dettrick Z, Lopez A . Reconstruction of long-term tobacco consumption trends in Australia and their relationship to lung cancer mortality. Cancer Causes Control. 2011; 22(7):1047-53. DOI: 10.1007/s10552-011-9781-0. View

Lew J, St John D, Xu X, Greuter M, Caruana M, Cenin D . Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. Lancet Public Health. 2017; 2(7):e331-e340. DOI: 10.1016/S2468-2667(17)30105-6. View

Barratt A . Overdiagnosis in mammography screening: a 45 year journey from shadowy idea to acknowledged reality. BMJ. 2015; 350:h867. DOI: 10.1136/bmj.h867. View

Hall M, Simms K, Lew J, Smith M, Brotherton J, Saville M . The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2018; 4(1):e19-e27. DOI: 10.1016/S2468-2667(18)30183-X. View

Brustugun O, Helland A . Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol. 2013; 53(1):134-7. DOI: 10.3109/0284186X.2013.783230. View

Stracci F, Zorzi M, Grazzini G . Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health. 2014; 2:210. PMC: 4209818. DOI: 10.3389/fpubh.2014.00210. View

Puliti D, Duffy S, Miccinesi G, de Koning H, Lynge E, Zappa M . Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012; 19 Suppl 1:42-56. DOI: 10.1258/jms.2012.012082. View

10.

Smittenaar C, Petersen K, Stewart K, Moitt N . Cancer incidence and mortality projections in the UK until 2035. Br J Cancer. 2016; 115(9):1147-1155. PMC: 5117795. DOI: 10.1038/bjc.2016.304. View

11.

. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149(3):185-91. DOI: 10.7326/0003-4819-149-3-200808050-00008. View

12.

Henley S, Miller J, Dowling N, Benard V, Richardson L . Uterine Cancer Incidence and Mortality - United States, 1999-2016. MMWR Morb Mortal Wkly Rep. 2018; 67(48):1333-1338. PMC: 6329484. DOI: 10.15585/mmwr.mm6748a1. View

13.

Nufer K, Raphael A, Soyer H . Dermoscopy and Overdiagnosis of Melanoma In Situ. JAMA Dermatol. 2018; 154(4):398-399. DOI: 10.1001/jamadermatol.2017.6448. View

14.

Pathirana T, Hayen A, Doust J, Glasziou P, Bell K . Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach. BMJ Open. 2019; 9(3):e022457. PMC: 6429722. DOI: 10.1136/bmjopen-2018-022457. View

15.

Luke C, Koczwara B, Karapetis C, Pittman K, Price T, Kotasek D . Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust N Z J Public Health. 2008; 32(4):383-9. DOI: 10.1111/j.1753-6405.2008.00260.x. View

16.

. Personal habits and indoor combustions. IARC Monogr Eval Carcinog Risks Hum. 2012; 100(Pt E):1-538. PMC: 4781577. View

17.

Luo Q, Yu X, Wade S, Caruana M, Pesola F, Canfell K . Lung cancer mortality in Australia: Projected outcomes to 2040. Lung Cancer. 2018; 125:68-76. DOI: 10.1016/j.lungcan.2018.09.001. View

18.

Feletto E, Yu X, Lew J, St John D, Jenkins M, Macrae F . Trends in Colon and Rectal Cancer Incidence in Australia from 1982 to 2014: Analysis of Data on Over 375,000 Cases. Cancer Epidemiol Biomarkers Prev. 2018; 28(1):83-90. DOI: 10.1158/1055-9965.EPI-18-0523. View

19.

Smith M, Canfell K . Impact of the Australian National Cervical Screening Program in women of different ages. Med J Aust. 2016; 205(8):359-364. DOI: 10.5694/mja16.00289. View

20.

Sitas F, Gibberd A, Kahn C, Weber M, Chiew M, Supramaniam R . Cancer incidence and mortality in people aged less than 75 years: changes in Australia over the period 1987-2007. Cancer Epidemiol. 2013; 37(6):780-7. DOI: 10.1016/j.canep.2013.09.010. View